aspirin has been researched along with Adenomatous Polyps in 18 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Adenomatous Polyps: Benign neoplasms derived from glandular epithelium. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "272 patients (naive for chronic aspirin use) with colorectal adenomas were randomly assigned to treatment with lysine acetylsalicylate 160 mg/day (n=73) or 300 mg/day (n=67) or placebo (n=132) for 4 years." | 9.16 | Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2012) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| ", mucosal prostaglandin E2 (PGE2) formation and transforming growth factor alpha (TGF-alpha) expression] in normal-appearing rectal mucosa from individuals with a history of adenomatous polyps." | 9.09 | Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. ( Barnes, CJ; Cameron, IL; Hamby-Mason, RL; Hardman, WE; Lee, M; Speeg, KV, 1999) |
| " Using patient samples from the randomized, placebo-controlled phase III selenium/celecoxib (Sel/Cel) trial for the prevention of colorectal adenomatous polyps, we analyzed plasma concentrations of 74 oxylipins in a subset of participants who received celecoxib (n = 90) or placebo (n = 95)." | 5.27 | Celecoxib use and circulating oxylipins in a colon polyp prevention trial. ( Alberts, DS; Hammock, BD; Lance, P; Martinez, JA; Roe, DJ; Schriewer, A; Thompson, PA; Wertheim, BC; Yang, J, 2018) |
| "272 patients (naive for chronic aspirin use) with colorectal adenomas were randomly assigned to treatment with lysine acetylsalicylate 160 mg/day (n=73) or 300 mg/day (n=67) or placebo (n=132) for 4 years." | 5.16 | Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2012) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| ", mucosal prostaglandin E2 (PGE2) formation and transforming growth factor alpha (TGF-alpha) expression] in normal-appearing rectal mucosa from individuals with a history of adenomatous polyps." | 5.09 | Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. ( Barnes, CJ; Cameron, IL; Hamby-Mason, RL; Hardman, WE; Lee, M; Speeg, KV, 1999) |
| "Colorectal cancer is the second leading cause of mortality in the United States." | 2.43 | Colorectal cancer prevention. ( Hawk, ET; Levin, B, 2005) |
| "To prospectively examine the association between non-steroidal anti-inflammatory drugs (NSAIDs) use (including dose and dosage schedule) and the recurrence of colorectal adenomas among individuals who were diagnosed with an adenoma at entry into a clinical trial." | 1.32 | Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). ( Albert, PS; Burt, R; Caan, B; Corle, D; Hasson, M; Iber, F; Kikendall, JW; Lance, P; Lanza, E; Paskett, E; Schatzkin, A; Shike, M; Tangrea, JA; Weissfeld, J; Woodson, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Renelus, BD | 1 |
| Dixit, D | 1 |
| Nguyen, PT | 1 |
| Njoku, KK | 1 |
| Patel, PB | 1 |
| Pintor-Jimenez, K | 1 |
| Yan, F | 1 |
| Buscaglia, JM | 1 |
| Woods, KE | 1 |
| Jamorabo, DS | 1 |
| Chan, AT | 1 |
| Moayyedi, P | 1 |
| Martinez, JA | 1 |
| Yang, J | 1 |
| Wertheim, BC | 1 |
| Roe, DJ | 1 |
| Schriewer, A | 1 |
| Lance, P | 2 |
| Alberts, DS | 1 |
| Hammock, BD | 1 |
| Thompson, PA | 1 |
| Benamouzig, R | 1 |
| Uzzan, B | 1 |
| Deyra, J | 1 |
| Martin, A | 1 |
| Girard, B | 1 |
| Little, J | 1 |
| Chaussade, S | 1 |
| Püllen, R | 1 |
| Dovjak, P | 1 |
| Broughton, T | 1 |
| Sington, J | 1 |
| Beales, IL | 1 |
| Tangrea, JA | 1 |
| Albert, PS | 1 |
| Lanza, E | 2 |
| Woodson, K | 1 |
| Corle, D | 1 |
| Hasson, M | 1 |
| Burt, R | 1 |
| Caan, B | 1 |
| Paskett, E | 1 |
| Iber, F | 1 |
| Kikendall, JW | 2 |
| Shike, M | 2 |
| Weissfeld, J | 1 |
| Schatzkin, A | 2 |
| Hawk, ET | 1 |
| Levin, B | 2 |
| Bresalier, RS | 1 |
| Sandler, RS | 2 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Oxenius, B | 1 |
| Horgan, K | 1 |
| Lines, C | 1 |
| Riddell, R | 1 |
| Morton, D | 1 |
| Lanas, A | 1 |
| Konstam, MA | 1 |
| Baron, JA | 2 |
| Arber, N | 1 |
| Eagle, CJ | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Zavoral, M | 1 |
| Lechuga, MJ | 1 |
| Gerletti, P | 1 |
| Tang, J | 1 |
| Rosenstein, RB | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Fowler, R | 1 |
| Wittes, J | 1 |
| Zauber, AG | 1 |
| Solomon, SD | 1 |
| Kim, S | 1 |
| Mott, LA | 1 |
| Burke, CA | 1 |
| Church, TR | 1 |
| McKeown-Eyssen, GE | 1 |
| Cole, BF | 1 |
| Haile, RW | 1 |
| Levine, JS | 1 |
| Ahnen, DJ | 1 |
| Möhler, M | 1 |
| Gutzler, F | 1 |
| Freedman, LS | 1 |
| Tangrea, J | 1 |
| Cooper, MR | 1 |
| Marshall, JR | 1 |
| Murphy, PA | 1 |
| Selby, JV | 1 |
| Schade, RR | 1 |
| Burt, RW | 1 |
| Cahill, J | 1 |
| Williams, CS | 1 |
| Smalley, W | 1 |
| DuBois, RN | 1 |
| Barnes, CJ | 1 |
| Hamby-Mason, RL | 1 |
| Hardman, WE | 1 |
| Cameron, IL | 1 |
| Speeg, KV | 1 |
| Lee, M | 1 |
| Bigler, J | 1 |
| Whitton, J | 1 |
| Lampe, JW | 1 |
| Fosdick, L | 1 |
| Bostick, RM | 1 |
| Potter, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence[NCT00224679] | Phase 3 | 300 participants | Interventional | 1997-03-31 | Terminated | ||
| The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia[NCT02324374] | 50 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for aspirin and Adenomatous Polyps
| Article | Year |
|---|---|
Colorectal cancer prevention.
Topics: Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colo | 2005 |
Clinical practice. Adenomatous polyps of the colon.
Topics: Adenoma; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Co | 2006 |
Aspirin use and potential mechanisms for colorectal cancer prevention.
Topics: Adenocarcinoma; Adenomatous Polyps; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Color | 1997 |
6 trials available for aspirin and Adenomatous Polyps
| Article | Year |
|---|---|
Celecoxib use and circulating oxylipins in a colon polyp prevention trial.
Topics: Adenomatous Polyps; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood | 2018 |
Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.
Topics: Adenoma; Adenomatous Polyps; Aged; Aspirin; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase Inhibi | 2012 |
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2005 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics.
Topics: Adenoma; Adenomatous Polyps; Adult; Aspirin; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Demogra | 1996 |
Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon.
Topics: Adenomatous Polyps; Aspirin; Biomarkers; Biopsy, Needle; Colonic Neoplasms; Dinoprostone; Double-Bli | 1999 |
9 other studies available for aspirin and Adenomatous Polyps
| Article | Year |
|---|---|
Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing advanced adenomatous polyps in Black patients.
Topics: Adenomatous Polyps; Aspirin; Chemoprevention; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2021 |
Signature Celebration of Gastroenterology, Colorectal Cancer.
Topics: Adenomatous Polyps; Anticarcinogenic Agents; Aspirin; Biomedical Research; Colonic Polyps; Colorecta | 2018 |
[Journal club].
Topics: Adenoma; Adenomatous Polyps; Anticoagulants; Aspirin; Coffee; Colonic Polyps; Colonoscopy; Colorecta | 2012 |
Statin use is associated with a reduced incidence of colorectal adenomatous polyps.
Topics: Adenomatous Polyps; Aspirin; Case-Control Studies; Confounding Factors, Epidemiologic; Dose-Response | 2013 |
Advances in reducing colorectal cancer risk. Colorectal cancer is the third most common cancer in women and the second leading cause of cancer death. These statistics belie how preventable this disease really is.
Topics: Adenomatous Polyps; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neopla | 2003 |
Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).
Topics: Adenoma; Adenomatous Polyps; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; As | 2003 |
Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States).
Topics: Adenomatous Polyps; Aspirin; Body Mass Index; Colorectal Neoplasms; Confidence Intervals; Female; Hu | 2006 |
[Administration of acetylsalicylic acid and risk of colorectal adenoma and carcinoma].
Topics: Adenomatous Polyps; Aspirin; Colorectal Neoplasms; Drug Administration Schedule; Follow-Up Studies; | 1995 |
CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic | 2001 |